Search Results - "Mouron, Silvana"

Uncoupling fork speed and origin activity to identify the primary cause of replicative stress phenotypes by Rodriguez-Acebes, Sara, Mourón, Silvana, Méndez, Juan

“…In growing cells, DNA replication precedes mitotic cell division to transmit genetic information to the next generation. The slowing or stalling of DNA…”
Get full text

Repriming of DNA synthesis at stalled replication forks by human PrimPol by Mourón, Silvana, Rodriguez-Acebes, Sara, Martínez-Jiménez, María I, García-Gómez, Sara, Chocrón, Sandra, Blanco, Luis, Méndez, Juan

“…DNA damage that causes replication forks to stall can be bypassed via translesion synthesis (TLS). New work has identified a bifunctional human primase and TLS…”
Get full text

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1 by Mouron, Silvana, Manso, Luis, Caleiras, Eduardo, Rodriguez-Peralto, Jose L, Rueda, Oscar M, Caldas, Carlos, Colomer, Ramon, Quintela-Fandino, Miguel, Bueno, Maria J

“…FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and…”
Get full text

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer by Zagorac, Ivana, Fernandez-Gaitero, Sara, Penning, Renske, Post, Harm, Bueno, Maria J., Mouron, Silvana, Manso, Luis, Morente, Manuel M., Alonso, Soledad, Serra, Violeta, Muñoz, Javier, Gómez-López, Gonzalo, Lopez-Acosta, Jose Francisco, Jimenez-Renard, Veronica, Gris-Oliver, Albert, Al-Shahrour, Fatima, Piñeiro-Yañez, Elena, Montoya-Suarez, Jose Luis, Apala, Juan V., Moreno-Torres, Amalia, Colomer, Ramon, Dopazo, Ana, Heck, Albert J. R., Altelaar, Maarten, Quintela-Fandino, Miguel

“…Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, we use high-throughput phosphoproteomics to build a functional TNBC…”
Get full text

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial by Quintela-Fandino, Miguel, Holgado, Esther, Manso, Luis, Morales, Serafin, Bermejo, Begoña, Colomer, Ramon, Apala, Juan V, Blanco, Raquel, Muñoz, Manuel, Caleiras, Eduardo, Iranzo, Vega, Martinez, Mario, Dominguez, Orlando, Hornedo, Javier, Gonzalez-Cortijo, Lucia, Cortes, Javier, Gasol Cudos, Ariadna, Malon, Diego, Lopez-Alonso, Antonio, Moreno-Ortíz, María C, Mouron, Silvana, Mañes, Santos

“…Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics,…”
Get full text

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition by Quintela-Fandino, Miguel, Apala, Juan V, Malon, Diego, Mouron, Silvana, Hornedo, Javier, Gonzalez-Cortijo, Lucia, Colomer, Ramon, Guerra, Juan

“…The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no…”
Get full text

Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells by Hühn, Daniela, Martí‐Rodrigo, Pablo, Mouron, Silvana, Hansel, Catherine, Tschapalda, Kirsten, Porebski, Bartlomiej, Häggblad, Maria, Lidemalm, Louise, Quintela‐Fandino, Miguel, Carreras‐Puigvert, Jordi, Fernandez‐Capetillo, Oscar

“…Among others, expression levels of programmed cell death 1 ligand 1 (PD‐L1) have been explored as biomarkers of the response to immune checkpoint inhibitors in…”
Get full text

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer by Ciscar, Marina, Trinidad, Eva M, Perez‐Chacon, Gema, Alsaleem, Mansour, Jimenez, Maria, Jimenez‐Santos, Maria J, Perez‐Montoyo, Hector, Sanz‐Moreno, Adrian, Vethencourt, Andrea, Toss, Michael, Petit, Anna, Soler‐Monso, Maria T, Lopez, Victor, Gomez‐Miragaya, Jorge, Gomez‐Aleza, Clara, Dobrolecki, Lacey E, Lewis, Michael T, Bruna, Alejandra, Mouron, Silvana, Quintela‐Fandino, Miguel, Al‐Shahrour, Fatima, Martinez‐Aranda, Antonio, Sierra, Angels, Green, Andrew R, Rakha, Emad, Gonzalez‐Suarez, Eva

“…Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to…”
Get full text

RINGO C is required to sustain the spindle-assembly checkpoint by Mourón, Silvana, de Cárcer, Guillermo, Seco, Esther, Fernández-Miranda, Gonzalo, Malumbres, Marcos, Nebreda, Angel R

“…RINGO/Speedy proteins are direct activators of Cdk1 and Cdk2 that have no sequence homology to cyclins. We have characterized the role in cell-cycle…”
Get full text

PrimPol, an Archaic Primase/Polymerase Operating in Human Cells by García-Gómez, Sara, Reyes, Aurelio, Martínez-Jiménez, María I, Chocrón, E. Sandra, Mourón, Silvana, Terrados, Gloria, Powell, Christopher, Salido, Eduardo, Méndez, Juan, Holt, Ian J, Blanco, Luis

“…We describe a second primase in human cells, PrimPol, which has the ability to start DNA chains with deoxynucleotides unlike regular primases, which use…”
Get full text

Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease by Knecht, Erwin, Criado-García, Olga, Aguado, Carmen, Gayarre, Javier, Duran-Trio, Lara, Garcia-Cabrero, Ana M., Vernia, Santiago, San Millán, Beatriz, Heredia, Miguel, Romá-Mateo, Carlos, Mouron, Silvana, Juana-López, Lucía, Domínguez, Mercedes, Navarro, Carmen, Serratosa, Jose M., Sanchez, Marina, Sanz, Pascual, Bovolenta, Paola, Rodríguez de Córdoba, Santiago

“…Lafora disease (LD), a fatal neurodegenerative disorder characterized by intracellular inclusions called Lafora bodies (LBs), is caused by recessive…”
Get full text

RINGO C is required to sustain the spindle-assembly checkpoint by Mourón, Silvana, de Cárcer, Guillermo, Seco, Esther, Fernández-Miranda, Gonzalo, Malumbres, Marcos, Nebreda, Angel R.

Get full text

Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics by Navarro, Paloma, Bueno, Maria J., Zagorac, Ivana, Mondejar, Tamara, Sanchez, Jesus, Mourón, Silvana, Muñoz, Javier, Gómez-López, Gonzalo, Jimenez-Renard, Veronica, Mulero, Francisca, Chandel, Navdeep S., Quintela-Fandino, Miguel

“…Epithelial malignancies are effectively treated by antiangiogenics; however, acquired resistance is a major problem in cancer therapeutics. Epithelial tumors…”
Get full text

DNA damage by cadmium and arsenic salts assessed by the single cell gel electrophoresis assay by Mourón, Silvana Andrea, Golijow, Carlos Daniel, Dulout, Fernando Noel

“…Human exposure to metals is frequent due to their ubiquity, wide use in industry, and environmental persistence. Direct and indirect genotoxic effects of…”
Get full text

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance by Manso, Luis, Mourón, Silvana, Tress, Michael, Gómez-López, Gonzalo, Morente, Manuel, Ciruelos, Eva, Rubio-Camarillo, Miriam, Rodriguez-Peralto, Jose Luis, Pujana, Miguel A, Pisano, David G, Quintela-Fandino, Miguel

“…We sought to identify genetic variants associated with disease relapse and failure to hormonal treatment in hormone-receptor positive breast cancer (HRPBC). We…”
Get full text

DNA–protein cross-links and sister chromatid exchanges induced by dimethylarsinic acid in human fibroblasts cells by Mourón, Silvana Andrea, Grillo, Claudia Alejandra, Dulout, Fernando Noel, Golijow, Carlos Daniel

“…Biotransformation of inorganic arsenic to form both methylarsinic acid (MA) and dimethylarsinic acid (DMA) has traditionally been considered as a mechanism to…”
Get full text

Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach by Bueno, Maria J, Mouron, Silvana, Quintela-Fandino, Miguel

“…Pathological angiogenesis involves complex and dynamic interactions between tumour cells and other lineages existing in the microenvironment of the tumour…”
Get full text

Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation by Bueno, Maria Jose, Mouron, Silvana, Caleiras, Eduardo, Martínez, Mario, Manso, Luis, Colomer, Ramón, Quintela-Fandino, Miguel

“…Background HER2, TROP2 and PD-L1 are novel targets in triple-negative breast cancer (TNBC). The combined expression status of these targets, and whether they…”
Get full text

Abstract PO2-02-13: A Mechanical Conditioning gene expression (MeCo) score detects the patients that benefit from neoadjuvant anti-fibrotic therapy in early HER2-negative breast cancer (HER2negBC) by Quintela-Fandino, Miguel, Watson, Adam, Grant, Adam, Mouneimne, Gus, Bueno, Maria J., Mouron, Silvana

“…Abstract Background: Extracellular matrix (ECM) stiffness in the tumor microenvironment is associated with aggressive features that lead to adverse clinical…”
Get full text

Abstract OT2-20-01: Rogaratinib, palbociclib and fulvestrant in advanced hormone receptor-positive (HR+), FGFR1/2-positive breast cancer: Phase I trial plus an expansion cohort by Pernas, Sonia, Hernando, Cristina, Bermejo, Begoña, Martinez-Jañez, Noelia, Saenz, Jose A García, Morales, Serafin, Manso, Luis, Silva, Jorge, Guerra, Juan A, Malon, Diego, Mouron, Silvana, Caleiras, Eduardo, Quintela-Fandino, Miguel

“…Abstract Background: Novel therapies are needed upon progression to first-line CDK4/6 inhibitor (CDKi) plus endocrine therapy in advanced HR+ breast cancer…”
Get full text